While the data release of the RayVa™ Phase 2a study is due in Q3, don't forget that APRI has other irons in the fire, including the launch of Virirec in France and Spain, which just happened in Q2 this year.
The day to day price of the stock has definitely sucked lately, but with a mere 75 million dollar MC, a thick pipeline and cash to fund operations until the end of the year, I won't be looking to reduce at this PPS.
I'll be waiting for the dust to settle and adding to my position.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.